2. Academic Validation
  3. Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects

Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects

  • Front Immunol. 2022 Feb 28:13:856327. doi: 10.3389/fimmu.2022.856327.
Chen-Xi Zhang 1,  Ye Tu 2,  Xiao-Chen Sun 3,  Da-Gui Chen 1,  Wan-Nian Zhang 4 5,  Chun-Lin Zhuang 4 5,  Zhi-Bin Wang 4 6,  Li Su 1
Affiliations

Affiliations

  • 1 Institute of Translational Medicine, Shanghai University, Shanghai, China.
  • 2 Department of Pharmacy, Shanghai East Hospital, Tongji University, Shanghai, China.
  • 3 School of Medicine, Shanghai University, Shanghai, China.
  • 4 School of Pharmacy, Naval Medical University, Shanghai, China.
  • 5 School of Pharmacy, Ningxia Medical University, Yinchuan, China.
  • 6 Department of Critical Care Medicine, School of Anesthesiology, Naval Medical University, Shanghai, China.
PMID: 35296098 DOI: 10.3389/fimmu.2022.856327
Abstract

Coronavirus Disease 2019 (COVID-19) infected by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been declared a public health emergency of international concerns. Cytokine storm syndrome (CSS) is a critical clinical symptom of severe COVID-19 patients, and the macrophage is recognized as the direct host cell of SARS-CoV-2 and potential drivers of CSS. In the present study, peramivir was identified to reduce TNF-α by partly intervention of NF-κB activity in LPS-induced macrophage model. In vivo, peramivir reduced the multi-cytokines in serum and bronchoalveolar lavage fluid (BALF), alleviated the acute lung injury and prolonged the survival time in mice. In human peripheral blood mononuclear cells (hPBMCs), peramivir could also inhibit the release of TNF-α. Collectively, we proposed that peramivir might be a candidate for the treatment of COVID-19 and other infections related CSS.

Keywords

COVID-19; acute lung injury; cytokine storm syndrome; multi-cytokines; peramivir.

Figures
Products